Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
251. |
ECCT/21/03/01 | Recombinant COVID-19 vaccine A global multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial to evaluate the efficacy, safety, and immunogenicity of… read more |
Principal Investigator(s) 1. Walter Jaoko Jaoko Site(s) in Kenya KAVI-institute of Clinical Research |
View |
252. |
ECCT/22/08/02 | AIM-LVRNA009-II_III-01 A Global Multi-center, Randomized, Blinded, Placebo-controlled Phase 2/3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 mRNA… read more |
Principal Investigator(s) 1. Bernhards Ogutu 2. Lucas Otieno 3. Videlis Nduba 4. Bernhards Ogutu 5. Jacqueline Mirera 6. Jacqueline Mirera … read more |
View |
253. |
ECCT/17/03/01 |
The POWER cohort A cohort for evaluation of open-label PrEP delivery among Kenyan and South African women |
Principal Investigator(s) 1. Dr. Stella Njuguna Site(s) in Kenya 1. Jaramogi Oginga Odinga Teaching and Referral Hospital. (Kisumu county) |
View |
254. |
ECCT/20/04/02 |
PROSYNK Study A 4-arm, open-label, individually randomized, controlled, phase-2, study of a probiotic and two synbiotics in young children in western Kenya. |
Principal Investigator(s) 1. Stephen Allen Site(s) in Kenya 1. Homa Bay County Referral Hospital (Homa Bay county) 2. Siaya County Referral Hospital (… read more |
View |
255. |
ECCT/13/04/08 |
Switching At Low HIV-1 RNA Into Fixed Dose Combinations SALIF Protocol Number: TMC278IFD3002 Amendment INT-1 |
Principal Investigator(s) 1. Edwin Onyango WERE 2. Milton Tony OMONDI 3. Gina OUATTARA 4. Gaudensia Nzembi MUTUA 5. Reena SHAH Site(s) in Kenya… read more |
View |